The antigenemia standard in the diagnosis and monitoring of an active CMV infection

CMV Brite™ Kit

Special features

- Complete kit for the diagnosis of an active CMV infection
- Detection at the single cell level
- Results within 4 hours after sample collection
- IVD CE for *In Vitro Diagnostic use*
- **FDA** cleared, USA

Applications

The CMV Brite™ Kit has a long history of being highly suitable for routine diagnostic use in monitoring an active CMV infection in at least three major groups of patients:

- *Bone marrow transplant recipients*
- *Solid organ transplant patients*
- *HIV infected persons and AIDS patients*

Rozenburglaan 13a • 9727 DL Groningen • The Netherlands
Tel. +31 (0)50 57 57 000 • *Fax* +31 (0)50 57 57 002 • *Email* marketing@iqproducts.nl • *Web* **www.iqproducts.nl**

Item	Description	Package size	Product code
CMV Brite™ Kit IVD CE 0344 FDA 510(k) #k951550	Complete kit for the diagnosis of an active CMV infection in 4 hours.	100 tests	VIR-CMV 100
Related products			
Item	**Description**	**Package size**	**Product code**
CMV Brite™ Turbo Kit IVD CE 0344 FDA 510(k) #k991650	Complete kit for the rapid diagnosis of an active CMV infection in 2 hours.	110 tests	VIR-CMV 110
CMV C10/C11 cocktail IVD CE 0344	Mix of 2 CMV pp65 monoclonal antibodies	200 tests	VIR-CMV C10/C11
CMV FITC Conjugate IVD CE 0344	Sheep anti-mouse-FITC	200 tests	VIR-FITC
CMV Control slides IVD CE 0344	CMV pp65 positive and negative cytospots	set of 5	VIR-CMV CS05

CMV infection in the healthy human, is usually subclinical. However, in the immunocompromised host and the developing foetus it may result in either localized or disseminated disease.
Clinical manifestations of CMV disease include pneumonia, retinitis, hepatitis, enteritis, and neurological disease. Despite improved treatment modalities, CMV infection may result in significant morbidity and mortality. Patients are at risk from both primary CMV infection and reactivation of latent infection.

Early and rapid diagnosis of active CMV infection is of great importance in avoiding over-treatment with immunosuppressive drugs and in guiding antiviral therapy.
The standard in CMV testing, antigenemia, is a non-culture technique that detects an active infection by blood sample analysis and is optimized for use in the CMV Brite™ Kit.

CMV Brite™, the FDA registered immunofluorescence antigenemia kit for in vitro CMV diagnosis, uses the well defined C10/C11 antibody cocktail to detect the CMV lower matrix phosphoprotein (pp65), an early antigen in virus replication, which is abundantly present in antigen-positive polymorphonuclear cells (PBMCs). The CMV Brite™ kit contains all the reagents and sample analysis is completed in 4 hours. The kit is available in 100 test format. A unique feature of this kit is the option for further susceptibility studies of the (positive) isolated PBMC fraction not possible with any other antigenemia kit.

Rozenburglaan 13a • 9727 DL Groningen • The Netherlands
Tel. +31 (0)50 57 57 000 • *Fax* +31 (0)50 57 57 002 • *Email* marketing@iqproducts.nl • *Web* **www.iqproducts.nl**